nilotinib: Clinical Trials

40 trials of nilotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 6 terminated, 3 unknown, 1 recruiting. 40 Phase 1, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 140Completed 29, Terminated 6, Unknown 3, Recruiting 1, Withdrawn 1
Phase 212Completed 6, Terminated 3, Unknown 2, Withdrawn 1

Follow nilotinib: new trials by email Literature Review of nilotinib trials Research Report on nilotinib

Trials (filtered) newest first · largest first

All 40 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.
XS003 (nilotinib), Tasigna (nilotinib) - Cancer
Phase 1CompletedXspray Pharma AB1282024-11-152025-08-22
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg - Metastatic Melanoma, BRAF Gene Mutation
Phase 1RecruitingRina Plattner302022-06-012026-02-13
KRT-232 and TKI Study in Chronic Myeloid Leukemia
KRT-232, Dasatinib, Nilotinib - Chronic Myeloid Leukemia
Phase 1 / Phase 2UnknownKartos Therapeutics, Inc.1092021-05-072022-03-21
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Nilotinib, Nilotinib Hydrochloride Monohydrate, Paclitaxel - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Phase 1CompletedOhio State University Comprehensive Cancer Center112020-12-112025-06-29
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Eicosapentaenoic Acid, Tyrosine kinase inhibitor - Chronic Myeloid Leukemia, Chronic Phase
Phase 1 / Phase 2TerminatedMilton S. Hershey Medical Center12020-09-142022-07-01
A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin
Metformin, Metformin + Nilotinib - Healthy
Phase 1CompletedHyewon Chung162020-07-232020-11-04
Nilotinib in Huntington's Disease
Nilotinib 150 MG - Huntington Disease
Phase 1UnknownGeorgetown University102018-11-152020-02-20
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
Nilotinib, Ruxolitinib - Leukemia, Chronic Myeloid
Phase 1 / Phase 2WithdrawnUniversity of Michigan Rogel Cancer Center2018-01-012021-02-16
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
Nilotinib + Paclitaxel - Solid Tumors
Phase 1CompletedNational Cancer Institute (NCI)472015-04-132026-09-28
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
MEK-162, Nilotinib, Questionnaires - Leukemia
Phase 1TerminatedM.D. Anderson Cancer Center12015-03-112020-02-12
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients
Nilotinib, Ruxolitinib - Chronic Myeloid Leukemia
Phase 1CompletedNovartis Pharmaceuticals52015-02-182019-05-01
Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
Nilotinib - Parkinson's Disease, Parkinson's Disease Dementia
Phase 1CompletedGeorgetown University122014-11-012015-12-16
A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Nilotinib + Cetuximab - Colorectal Cancer, Head and Neck Cancer
Phase 1TerminatedGeorgetown University152014-05-012019-02-08
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Asciminib (ABL001), Nilotinib, Imatinib - Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Phase 1CompletedNovartis Pharmaceuticals3262014-04-242024-03-18
Pharmacokinetic Comparison of XS003 and Tasigna
XS003, Tasigna - Healthy
Phase 1CompletedXSpray Microparticles272013-12-012014-11-11
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia
Phase 1 / Phase 2CompletedUniversity Health Network, Toronto42013-08-012020-11-02
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
Dasatinib, Imatinib Mesylate, Nilotinib - Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission
Phase 1TerminatedM.D. Anderson Cancer Center82013-07-242025-06-03
Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults
Nilotinib, Vinblastine - Refractory Low-grade Gliomas, Recurrent Low-grade Gliomas
Phase 1CompletedGustave Roussy, Cancer Campus, Grand Paris352013-05-292022-05-27
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia
Phase 1CompletedH. Lee Moffitt Cancer Center and Research Institute112013-02-212021-01-05
Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
Nilotinib, interferon-alfa - Chronic Myeloid Leukemia
Phase 1CompletedNovartis Pharmaceuticals42012-04-012015-05-05

Showing 20 of 40. Sign in to see all of them.

Conditions studied

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (15)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (7)  ·  Leukemia, Myeloid, Chronic-Phase (5)  ·  Blast Crisis (3)  ·  Neoplasms (3)  ·  Gastrointestinal Stromal Tumors (2)  ·  Leukemia (2)  ·  Leukemia, Myeloid, Accelerated Phase (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Carcinoma, Squamous Cell (1)  ·  Chondrosarcoma (1)  ·  Chordoma (1)  ·  Colorectal Neoplasms (1)  ·  Head and Neck Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (14)  ·  Georgetown University (3)  ·  M.D. Anderson Cancer Center (2)  ·  University Health Network, Toronto (2)  ·  Broto, Javier Martín, M.D. (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Gruppo Italiano Trapianto di Midollo Osseo (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Hyewon Chung (1)  ·  Jan Beumer (1)  ·  Kartos Therapeutics, Inc. (1)  ·  Massachusetts General Hospital (1)  ·  Milton S. Hershey Medical Center (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (21)  ·  Italy (9)  ·  France (8)  ·  Germany (8)  ·  Canada (6)  ·  Spain (6)  ·  United Kingdom (5)  ·  Netherlands (4)  ·  South Korea (4)  ·  Japan (3)  ·  Australia (2)  ·  Austria (2)  ·  Denmark (2)  ·  Poland (2)  ·  Singapore (2)

Top investigators

Alice P Chen, M.D. (1)  ·  Andreas Hochhaus, Prof. Dr. med. (1)  ·  Ann W Gramza, MD (1)  ·  Attilio Olivieri, MD (1)  ·  David Miklos (1)  ·  Dennis Kim, MD/PhD (1)  ·  Edwin Choy, MD, PhD (1)  ·  George Chen (1)  ·  Hagop M. Kantarjian, MD (1)  ·  Hyewon Chung, MD, PhD (1)  ·  Jan H. Beumer, PharmD, PhD (1)

Results publications

PMID 16775235, PMID 17715389, PMID 18048643, PMID 20110053, PMID 21098399, PMID 23065514, PMID 23547655, PMID 24057647, PMID 26002753, PMID 27434297, PMID 29051021, PMID 30340199, PMID 31826340, PMID 32666050, PMID 33142018, PMID 35764773, PMID 38755421, PMID 39374521, PMID 40680102

NIH funding

2005 (1), 2009 (1), P01CA018029 (1), P30CA015704 (1), P30CA016672 (1), R01CA238946 (1), R01CA258751 (1)